Insider · CIK 0002060594
Namandje Bumpus
Files at RXRX (RECURSION PHARMACEUTICALS, INC.). First filing Jun 4, 2026, latest Jun 22, 2026.
In brief
Namandje Bumpus files SEC Form 4 as director at RXRX (RECURSION PHARMACEUTICALS, INC.). Since Jun 4, 2026, Namandje Bumpus has reported 0 open-market buys worth $0 and 2 open-market sells worth $28k, the latest filed on Jun 22, 2026.
A track record needs three past buys with six months of prices behind them; Namandje Bumpus has 0, so none is measured yet.
The newest scored trade: sold $13k of RXRX on Jun 18, 2026, filed Jun 22, 2026, scored 10 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $28k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RXRX: RECURSION PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | RECURSION PHARMACEUTICALS, INC. | $13k 3,963 shares | -3% | +14% from low-52% from high | |
| 10Weak | RECURSION PHARMACEUTICALS, INC. | $16k 4,386 shares | -9% | +22% from low-49% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 18, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | 3,963 0.00% of outstanding | $13k | Jun 18, 2026 | $16k |
| Jun 3, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | 4,386 0.00% of outstanding | $16k | Jun 3, 2026 | none |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock10b5-1 | +88,424 | $0.00 | $0 | 131,595 | Jun 22, 2026 |
| Jun 18, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -3,963 | $3.18 | $13k | 127,632 | Jun 22, 2026 |
| Jun 3, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -4,386 | $3.54 | $16k | 43,171 | Jun 4, 2026 |
| Jun 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +11,008 | $0.00 | $0 | 47,557 | Jun 23, 2025 |
| Jun 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +22,016 | $0.00 | $0 | 22,016 | Jun 23, 2025 |
| Mar 17, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +36,549 | $0.00 | $0 | 36,549 | Mar 19, 2025 |
| Mar 17, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +73,099 | $0.00 | $0 | 73,099 | Mar 19, 2025 |
Questions about Namandje Bumpus
Answered from the filings on this page, as of the latest one.
Is Namandje Bumpus buying or selling?
In the last 12 months Namandje Bumpus reported 0 open-market buys worth $0 and 2 open-market sells worth $28k on SEC Form 4; the latest was sold $13k of RXRX on Jun 18, 2026. Grants, option exercises and tax withholding are not counted.
How did Namandje Bumpus's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Namandje Bumpus has 0.
Where does Namandje Bumpus file Form 4?
Namandje Bumpus has filed Form 4 at RXRX (RECURSION PHARMACEUTICALS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.